HEALTH MART SYSTEMS INC

Item 7 in the 2025 FDD pegs initial investment at $261,870-$833,870, varying sharply by whether you're launching unopened locations or converting open pharmacies—lower end likely favors conversions with existing infrastructure. Fees keep it lean: zero royalty or ad fund, just $390 monthly for core services like the web portal, training, purchasing co-op perks, and marketing tools; add-ons include $50/mo front-end solutions or $200-500/mo for merchandising rebates. No Item 19 disclosure means no official revenue or profit benchmarks, a red flag in retail where margins hover 2-4% on prescriptions amid fierce competition from chains, groceries, and online players—buyers must dig into FDD Items 20-21 for closure stats.

System size impresses at 4,346 locations (down 4% from 4,543 in 2024), signaling maturity over explosive growth, with headquarters in Irving, TX, leveraging McKesson's supply chain dominance. SBA financing shines: 133 loans averaging $726,567 and a low 3.8% default rate suggest credible bankability for qualified buyers. For evaluators, probe FDD Items 19 absence via current franchisee outreach, scrutinize contraction drivers like market saturation, and model cash flows assuming $1M+ annual sales to cover slim fees—ideal for experienced pharmacists eyeing scale without losing independence.